Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q3 FY2024 Earnings Presentation
12 slides from Natco Pharma's earnings presentation, Feb 15, 2024
Slide 1: Exchange filing cover letter: Q3 FY24 Investor Presentation
15th February 2024 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam, Sub: - Q3 FY24
Slide 2: Earnings Presentation Q3FY24
Earnings Presentation Q3FY24
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Table of Contents
Table of Contents 1 Q3FY24 Key Business & Financial Highlights 2 Financial Summary 3 Product Portfolio & Pipeline Natco Pharma Limited – Earnings Presentation – Q3FY24
Slide 5: Q3FY24 Key Business & Financial Highlights
1 Q3FY24 Key Business & Financial Highlights Natco Pharma Limited – Earnings Presentation – Q3FY24
Slide 6: Q3FY24 – Key Business & Financial Highlights
Q3FY24 – Key Business & Financial Highlights Total Revenue stood at INR 7,956 mn|Pharma Export Formulations at INR 6,056 mn | Domestic Formulations at INR 994 mn | Agchem at INR 141 mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 3,051 mn |EBITDA Margin for Q3FY24 was at 3
Slide 7: Q3FY24 – Quarterly Performance
Q3FY24 – Quarterly Performance Revenue Breakup (INR Mn) Revenue Breakup (%) – Q3FY24 6% 4% 2% Revenue Division Q3FY24 Q3FY23 Q2FY24 12% A) API Revenue 463 426 778 B) Formulation 76% B1) Formulation – Exports (incl profit Export Formulation Domestic Formulation share, license income, export service 6
Slide 8: Financial Summary
2 Financial Summary Natco Pharma Limited – Earnings Presentation – Q3FY24
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Q3FY24 Q3FY23 Q2FY24 Total Revenue 7,956 5,133 10,608 Total Expenses (before finance cost and depreciation) 4,905 3,866 5,734 Earnings before interest, tax, depreciation and amortization (EBITDA) 3,051 1,267 4,874 EBITDA Marg
Slide 10: Key Product Pipeline
3 Key Product Pipeline Natco Pharma Limited – Earnings Presentation – Q3FY24
Slide 11: Key Product Pipeline - USA
Key Product Pipeline - USA 23 Para IVs in the pipeline 15 Approved (either tentative or fully) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline Therapeutic Therapeutic Key Brand Molecule Key Brand Molecule Segment / Primary Indication Segment / Primary Indication Tracleer
Slide 12: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546564 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma